FDA Approves Teva's Once-Monthly Injectable Olanzapine
(RTTNews) - Friday, Teva Pharmaceuticals (TEVA) announced that the U.S. FDA has approved WELTRUZA (olanzapine) extended-release injectable suspension for adults with schizophrenia.
We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.